SC
DGX icon

Samlyn Capital’s Quest Diagnostics DGX Stock Holding History

Samlyn Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-637,800
Closed -$38.7M – 97
2013
Q2 		$38.7M Buy
+637,800
New +$38M 1.13% 38

Other funds holding DGX

AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Samlyn Capital's DGX Position: Q3 2013 in Review

Samlyn Capital sold out of Quest Diagnostics (DGX) in Q3 2013, closing a stake of 637,800 shares — an estimated $38.7M sold.

Samlyn Capital first reported a position in DGX in Q2 2013 and held it in 1 quarter. The position peaked at $38.7M in Q2 2013. 425 funds tracked by Wall St. Rank hold DGX as of Q3 2013.

  • Samlyn Capital reported no remaining Quest Diagnostics position as of Q3 2013 after selling out during the quarter.
  • Samlyn Capital sold 637,800 Quest Diagnostics shares in Q3 2013, an estimated $38.7M.
  • Samlyn Capital first reported a position in Quest Diagnostics in Q2 2013 and held it in 1 quarter.
  • Samlyn Capital's Quest Diagnostics position peaked at $38.7M in Q2 2013.
  • 425 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2013.

Based on Samlyn Capital's 13F filing for Q3 2013, filed 14 Nov 2013.